Mirum Pharmaceuticals (MIRM) Depreciation & Amortization (CF) (2019 - 2026)

Mirum Pharmaceuticals' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 13.58% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $25.1 million (up 4.37% YoY), while the FY2025 annual figure was $24.2 million, up 2.6% from the prior year.
• Depreciation & Amortization (CF) was $6.9 million for Q1 2026 at Mirum Pharmaceuticals, up from $6.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $6.9 million in Q1 2026 to a low of $342000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $4.0 million across 5 years, with a median of $5.7 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) jumped 1204.76% in 2022, then climbed 0.12% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.2 million in 2022, then soared by 357.45% to $5.5 million in 2023, then climbed by 10.23% to $6.1 million in 2024, then gained by 0.3% to $6.1 million in 2025, then gained by 13.17% to $6.9 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $6.9 million (Q1 2026), $6.1 million (Q4 2025), and $6.1 million (Q3 2025), per Business Quant data.